Crystalline forms of...

Details Crystalline forms of... Crystalline forms of...

2011-01-04

2011-01-04

Shiao, Rei-tsang (Department: 1628)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

active

07863456

ABSTRACT:
The present invention relates to crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid, pharmaceutical compositions and dosage forms comprising the crystalline forms, methods of making the crystalline forms and methods for their use for the treatment, prevention or management of diseases ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay.

REFERENCES:
patent: 6660753 (2003-12-01), Van Wagenen et al.
patent: 6759538 (2004-07-01), Singh et al.
patent: 6992096 (2006-01-01), Karp et al.
patent: 7041685 (2006-05-01), Cai et al.
patent: 7112595 (2006-09-01), Van Wagenen et al.
patent: 7153880 (2006-12-01), Singh et al.
patent: 7202262 (2007-04-01), Karp et al.
patent: 2004/0132726 (2004-07-01), Arora et al.
patent: 2005/0075375 (2005-04-01), Vourloumis et al.
patent: 2005/0164973 (2005-07-01), Karp et al.
patent: 2006/0089365 (2006-04-01), Hintermann
patent: 2006/0148863 (2006-07-01), Karp et al.
patent: 2006/0148864 (2006-07-01), Karp et al.
patent: 2007/0161687 (2007-07-01), Karp et al.
patent: WO 2006/110483 (2006-10-01), None
U.S. Appl. No. 11/899,813, filed Sep. 6, 2007, Almstead et al.
Knapman, 2000, “Polymorphic predictions—Understanding the nature of crystalline compounds can be critical in drug development and manufacture,” Modern Drug Discovery, Mar. 2000, pp. 53-57.
Welch et al 2007, “PTC124 Targets Genetic Disorders Caused by Nonsense Mutations,”Nature 447:87-91.
Supplementary Information from Welch et al., 2007, “PTC124 Targets Genetic Disorders Caused by Nonsense Mutations,”Nature 447:87-91 (pp. 1-23).
Hirawat et al., 2007, “Safety, Tolerability, and Pharmacokinetics of PTC124, a Nonaminoglycoside Nonsense Mutation Suppressor, Following Single- and Multiple-Dose Administration to Healthy Male and Female Adult Volunteers,”Journal of Clinical Pharmacology 47(4):430-444.
Du et al., 2008, “PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model.”PNAS 105(6):2064-2069.
Kerem et al., 2008, “Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial,”The Lancet 372:719-27.
Auld et al., 2009, “Mechanism of PTC124 activity in cell based luciferase assays of nonsense codon suppression,”PNAS Early Edition:1-6 (document sent via fax Jan. 28, 2009).
Auld et al., 2009, “Mechanism of PTC124 activity in cell based luciferase assays of nonsense codon suppression,”PNAS Early Edition:1-6 (document previously available from www.genome.gov website in Feb. 2008).
Auld et al., 2009, “Mechanism of PTC124 activity in cell based luciferase assays of nonsense codon suppression,”PNAS Early Edition: 1-6.
Supplemental Information Methods from Auld et al., 2009, “Mechanism of PTC124 activity in cell based luciferase assays of nonsense codon suppression,”PNAS Early Edition:1-6 (pp. 1-17).
Announcement by PTC Therapeutics, Inc. and Genzyme Corporation dated Mar. 3, 2010.
Auld et al., 2010, “Molecular basis for the high-affinity binding and stabilization of firefly luciferase by PTC124,”PNAS 107(11):4878-4883.
Braga and Grepioni, 2005, “Making crystals from crystals: a green route to crystal engineering and polymorphism,”Chem. Commun.:3635-3645.
Jones et al., 2006, Pharmaceutical Cocrystals: An Emerging Approach to Physical Property Enhancement,MRS Bulletin 31:875-879.
Price, 2004, “The computational prediction of pharmaceutical crystal structures and polymorphism,”Advanced Drug Delivery Reviews 56:301-319.
Bernstein, 2004, “Crystal Structure Prediction and Polymorphism,”ACA Transactions 39:14-23.
U.S. Appl. No. 60/269,847, filed Feb. 21, 2001, Van Wagenen et al.
U.S. Appl. No. 60/149,464, filed Aug. 19, 1999, Van Wagenen et al.
U.S. Appl. No. 60/405,472, filed Aug. 23, 2002, Singh et al.
U.S. Appl. No. 60/350,107, filed Nov. 2, 2001, Singh et al.

Affiliated with

Also associated with

Rating

Crystalline forms of... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Crystalline forms of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystalline forms of... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2666244